Scholar Rock Ignites Retail Buzz As Stock Rockets 300% On …

Scholar Rock said it plans to submit a U.S. Biologics License Application and seek European Union marketing authorization in Q1 2025

CouponFollow Extension

300%
OFF

Scholar Rock Ignites Retail Buzz As Stock Rockets 300% On …

3 weeks from now

Scholar Rock said it plans to submit a U.S. Biologics License Application and seek European Union marketing authorization in Q1 2025

barchart.com

77%
OFF

Scholar Rock’s Retail Following Jumps 77% After Therapy

3 weeks from now

Oct 8, 2024 · Scholar Rock’s Retail Following Jumps 77% After Therapy Trial Win, Firm Announces $275M Share Sale ... dropped more than 9% on Tuesday following a massive …

stocktwits.com

300%
OFF

Scholar Rock Stock Quadruples On Positive Trial Data - MSN

3 weeks from now

The results were strong enough to send the stock, which trades under the ticker SRRK, soaring more than 300% to above $30 per share on Monday morning from its Friday closing price of …

msn.com

300%
OFF

Scholar Rock’s Shares Soar 300% After Phase III Win In ... - BioSpace

3 weeks from now

Oct 8, 2024 · Scholar Rock on Monday announced that its investigational myostatin blocker apitegromab aced the Phase III SAPPHIRE trial in spinal muscular atrophy, demonstrating …

biospace.com

300%
OFF

Scholar Rock Shares Jump 300% After Rare Disease Drug Scores Trial …

3 weeks from now

Oct 7, 2024 · Scholar Rock is expected to report data from the obesity studies in the second quarter of 2025. Its shares were trading at $30.38. Until Friday's close of $7.42, the stock had …

reuters.com

300%
OFF

HSAPAY On LinkedIn: Scholar Rock Ignites Retail Buzz As Stock …

3 weeks from now

Only put off until tomorrow what you are willing to die having left undone. Scholar Rock's Muscle-Targeted Therapy Trial Success Propels Stock 300%…

linkedin.com

300%
OFF

Scholar Rock Seeks Equity Raise After Stock Skyrockets Over 300%

3 weeks from now

Oct 7, 2024 · ** Biopharma firm Scholar Rock NASDAQ:SRRK looks to capitalize on its soaring stock price by raising equity** SRRK skyrocketed 362% to close at nearly 3-yr high $34.28 on …

tradingview.com

$300
OFF

Scholar Rock Announces Pricing Of Upsized $300 Million Public …

3 weeks from now

CAMBRIDGE, Mass., October 09, 2024--Scholar Rock Holding Corporation (Nasdaq: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal …

yahoo.com

FAQs about Scholar Rock Ignites Retail Buzz As Stock Rockets 300% On … Coupon?

Is scholar rock a good stock to buy for the Embraze trial?

At recent prices, Scholar Rock boasts a $2.5 billion market cap. This is an appropriate valuation for a company likely to earn approval for an SMA treatment late next year. That said, this stock's present valuation isn't pricing in any success for the Embraze trial. Scholar Rock is a high-risk stock best avoided by most individual investors. ...

Is scholar rock a good stock to buy right now?

Scholar Rock is a high-risk stock best avoided by most individual investors. If you have an extremely high tolerance for risk, though, adding some shares to a well-diversified portfolio could be a smart move right now. Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. ...

Is scholar rock a candidate for a larger biopharma company?

In his Monday note, Yee wrote that the new data makes Scholar Rock an attractive candidate for acquisition by a larger biopharma company active in spinal muscular atrophy, or related areas. Scholar Rock shares had traded as high as $68 in March 2021, but the stock has plummeted since, along with many other the smaller and midsize biotech players. ...

How much money will scholar rock make from the offering?

The gross proceeds from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by Scholar Rock and assuming no exercise of the pre-funded warrants, are expected to be approximately $300 million. ...

Will scholar rock be able to commercialize apitegromab?

Based on these promising results, Scholar Rock will submit applications to the FDA and the EMA in the first quarter of 2025. Furthermore, the company initiated an underwritten public offering of $275 million of shares of its common stock to support commercialization efforts for Apitegromab, among other operational needs. ...